Of the studies that have assessed HER2 expression in CTCs, the majority have evaluated discordance rates between CTC HER2 expression and that of the primary breast cancer, with few assessing the prognostic role of HER2+ CTCs or the efficacy of anti-HER2 therapy. The gene discussed is ERBB2; the disease is breast carcinoma.